Allergan partners with Heptares to develop treatments for neurological disorders
Under the deal, Allergan will pay $125m upfront to Heptares for exclusive global rights to a portfolio of treatments for neurological disorders. Heptares is also eligible for milestone
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.